

HETEROCYCLES, Vol. 80, No. 2, 2010, pp. 841 - 846. © The Japan Institute of Heterocyclic Chemistry
 Received, 31st July, 2009, Accepted, 4th September, 2009, Published online, 14th September, 2009
 DOI: 10.3987/COM-09-S(S)100


DIVERGENT SYNTHESIS OF LAMELLARIN α 13-SULFATE, 20-SULFATE, and 13,20-DISULFATE

Tsutomu Fukuda,^a Takeshi Ohta,^a Sho Saeki,^a and Masatomo Iwao^{b*}


^aGraduate School of Science and Technology, and ^bDepartment of Applied Chemistry, Faculty of Engineering, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan, e-mail: iwao@nagasaki-u.ac.jp

Abstract – A divergent synthesis of three sulfate derivatives of lamellarin α , namely, lamellarin α 13-sulfate (**2**), 20-sulfate (**1**), and 13,20-disulfate (**4**) has been achieved *via* a common intermediate (**6**) in which 13-OH and 20-OH of the lamellarin core are differentially protected by MOM and benzyl groups, respectively. Compound (**6**) in turn was prepared using sequential Suzuki-Miyaura coupling of 3,4-dihydroxypyrrole bistriflate (**7**) as a key reaction.

Lamellarins and the related marine pyrrole alkaloids have attracted considerable attention due to their unique structures and highly useful biological activities.¹ Lamellarin α 20-sulfate (**1**) was isolated from the unidentified ascidian collected from the Arabian Sea near Trivandrum, India, by Faulkner and co-workers.² They demonstrated that **1** inhibits HIV-1 integrase selectively and growth of the HIV-1 virus in cell culture.² Because cytotoxicity of **1** is quite low, this natural product has been regarded as a new type of lead compound for development of anti-HIV agents. An attempted synthesis of lamellarin α 20-sulfate (**1**) and 13-sulfate (**2**) from lamellarin α (**3**) by titration with DMF-SO₃ complex was reported by Faulkner and coworkers in 2002.³ Unfortunately, however, they obtained only lamellarin 13,20-disulfate (**4**) in low yield. Recently, we reported the first total synthesis of lamellarin α 20-sulfate (**1**) from the differentially protected lamellarin α (**5**).⁴ The selective introduction of sulfate group at




20-OH was effected by a sequence involving selective debenzoylation of 20-OBn, 2,2,2-trichloroethylsulfonation of the resulting 20-OH, deprotection of 13-O*i*-Pr, and final reductive cleavage of the 2,2,2-trichloroethyl ester moiety.^{5,6} For the structure-activity relationship studies concerning integrase inhibition and anti-HIV activity, we needed to prepare lamellarin α 13-sulfate (**2**) and 13,20-disulfate (**4**) also. It was revealed, however, the synthesis of **2** from **5** was difficult because debenzoylation at 20-OBn occurred simultaneously during deprotection at 13-O*i*-Pr under the standard BCl₃ conditions. Thus, we designed a new lamellarin α derivative (**6**) in which 13-OH was protected by a more labile methoxymethyl (MOM) group. In this communication, we report a divergent synthesis of lamellarin α sulfate derivatives (**1**), (**2**), and (**4**) from the common intermediate (**6**) which in turn can be obtained from 3,4-dihydroxypyrrole bistriflate (**7**) and arylboronic acids (**8**), (**9**) using the previously established procedure developed in our laboratories (Scheme 1).^{4,5}




Scheme 1

The synthesis of arylboronic acid (**8**) is shown in Scheme 2. Isovanillin (**10**) was benzylated with benzyl bromide to give *O*-benzylisovanillin (**11**) in 86% yield.⁷ Baeyer-Villiger oxidation of **11** with *m*-chloroperbenzoic acid (*m*CPBA) followed by methanolysis afforded the phenol (**12**) in 90% yield. After MOM protection of the phenolic hydroxy group, the resulting **13** was regioselectively brominated by *N*-bromosuccinimide (NBS) to give **14** in 97% yield. Bromine–lithium exchange of **14** with *tert*-butyllithium followed by treatment with trimethyl borate afforded the desired arylboronic acid (**8**). Another arylboronic acid (**9**) was prepared according to the procedure shown in Scheme 3. C-2-




Scheme 2. *Reagents and conditions:* (a) BnBr (1.1 equiv), K₂CO₃, acetone, reflux, 4.5 h (86%); (b) (1) *m*CPBA (1.5 equiv), CH₂Cl₂, 0 °C, 3 h, (2) K₂CO₃, MeOH, rt, 1.5 h (90%); (c) MOM-Cl (1.5 equiv), *i*-Pr₂NEt, CH₂Cl₂, 0 °C, 1 h then rt, 48 h (87%); (d) NBS (1.0 equiv), DMF, 0 °C, 1 h (97%); (e) (1) *tert*-BuLi (2.1 equiv), THF, −78 °C, 1 h, (2) B(OMe)₃ (1.5 equiv), −78 °C, 1 h then rt, 1 h (99%).

selective bromine–lithium exchange of commercially available 2,4-dibromoanisole (**15**) followed by boration and oxidation gave the phenol (**16**) in 78% yield.⁸ After MOM protection of the phenolic hydroxy group, the resulting **17** was converted into the arylboronic acid (**9**) *via* bromine–lithium exchange with *tert*-butyllithium followed by treatment with trimethyl borate.



Scheme 3. *Reagents and conditions:* (a) (1) *n*-BuLi (1.1 equiv), THF, $-78\text{ }^{\circ}\text{C}$, 1 h, (2) B(OMe)₃ (1.5 equiv), $-78\text{ }^{\circ}\text{C}$, 1 h then rt, 1 h, (3) AcOH, H₂O₂, rt, 16 h (78%); (b) MOM-Cl (1.5 equiv), K₂CO₃, acetone, $0\text{ }^{\circ}\text{C}$, 1 h then reflux, 19 h (96%); (c) (1) *tert*-BuLi (2.1 equiv), THF, $-78\text{ }^{\circ}\text{C}$, 1 h, (2) B(OMe)₃ (1.5 equiv), $-78\text{ }^{\circ}\text{C}$, 1 h then rt, 1 h (72%).


The synthesis of lamellarin α 13-sulfate (**3**) was shown in Scheme 4. Suzuki-Miyaura coupling of the



Scheme 4. *Reagents and conditions:* (a) **8** (1.2 equiv), Pd(PPh₃)₄ (2 mol%), Na₂CO₃, water, THF, reflux, 3 h (74%); (b) (1) concd HCl, MeOH, reflux, 1 h, (2) *p*-TsOH, CH₂Cl₂, reflux, 2 h (93%); (c) **9** (2.0 equiv), Pd(PPh₃)₄ (8 mol%), Na₂CO₃, water, THF, reflux, 8 h (95%); (d) (1) 40% aqueous KOH, EtOH, reflux, 2 h, (2) PPTS, CH₂Cl₂, reflux, 24 h (61%); (e) Cu₂O (1.0 equiv), quinoline, $220\text{ }^{\circ}\text{C}$, 10 min (83%); (f) PIFA (1.2 equiv), BF₃·OEt₂, CH₂Cl₂, $-40\text{ }^{\circ}\text{C}$, 1.5 h (62%); (g) DDQ (1.0 equiv), CH₂Cl₂, reflux, 30 h (87%); (h) concd HCl, MeOH-CH₂Cl₂ (1:2), $45\text{ }^{\circ}\text{C}$, 2 h (99%); (i) CCl₃CH₂OSO₂Cl (2.0 equiv), Et₃N, DMAP, CH₂Cl₂, rt, 5 h (89%); (j) H₂, 10% Pd-C, EtOAc, rt, 4 h (61%); (k) (1) Zn powder (3.0 equiv), HCO₂NH₄ (6.0 equiv), THF-MeOH (1:1), rt, 2 h, (2) Amberlite IRC-50 (Na⁺ form), MeOH, (3) Sephadex LH-20, MeOH-CH₂Cl₂ (1:1) (61%).

bistriflate (**7**) with 1.2 equiv of an arylboronic acid (**8**) under the standard conditions [$\text{Pd}(\text{PPh}_3)_4$ (2 mol%), Na_2CO_3 , water, THF, reflux, 3 h]⁹ gave the mono-arylated pyrrole (**18**) in 74% yield. Compound (**18**) was converted into the lactone (**19**) by treatment with hydrochloric acid in methanol followed by acid-catalyzed lactonization in 93% yield. The second cross-coupling of **19** with an arylboronic acid (**9**) (2.0 equiv) using 8 mol% of $\text{Pd}(\text{PPh}_3)_4$ afforded **20** in 95% yield. Compound (**20**) was converted into the acid (**21**) by alkaline hydrolysis followed by acid-catalyzed relactonization in 61% yield. Decarboxylation of **21** in hot quinoline in the presence of copper(I) oxide produced **22**.¹⁰ Intramolecular oxidative biaryl coupling of **22** under Kita's conditions¹¹ using phenyliodine bis(trifluoroacetate) (PIFA)-boron trifluoride etherate afforded the cyclized product (**23**) in 62% yield. Treatment of **23** with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in refluxing dichloromethane produced the common intermediate (**6**). Deprotection of the MOM group by treatment with hydrochloric acid in methanol afforded **24**, which was reacted with 2,2,2-trichloroethyl chlorosulfate in dichloromethane to give the mixed sulfate (**25**) in 89% yield.⁶ Hydrogenolysis of **25** over palladium on charcoal for 4 h at room temperature afforded debenzylated **26** in 61% yield. Final reductive deprotection of the 2,2,2-trichloroethyl ester with $\text{Zn}/\text{HCO}_2\text{NH}_4$ followed by ion exchange over Amberlite IRC-50 (Na^+ form) and Sephadex purification produced lamellarin α 13-sulfate (**2**)¹² in 61% yield.

The syntheses of lamellarin α 20-sulfate (**1**) and lamellarin α 13,20-disulfate (**4**) are shown in Scheme 5. Compound (**6**) was debenzylated by hydrogenolysis over palladium on charcoal to give **27** in 99% yield. 2,2,2-Trichloroethylsulfonation of **27** in a similar manner as described above provided **28** in 69% yield. Selective removal of MOM protecting group provided **29** in 81% yield. Treatment of **29** with $\text{Zn}/\text{HCO}_2\text{NH}_4$ followed by ion exchange over Amberlite IRC-50 (Na^+ form) and Sephadex purification produced lamellarin α 20-sulfate (**1**)¹³ in 85% yield. Deprotection of MOM group from **27** with



Scheme 5. *Reagents and conditions*: (a) H_2 , 10% Pd-C, EtOAc, rt, 2 h (99%); (b) $\text{CCl}_3\text{CH}_2\text{OSO}_2\text{Cl}$ (2.0 equiv), Et_3N , DMAP, CH_2Cl_2 , rt, 2.5 h (69%); (c) concd HCl, MeOH- CH_2Cl_2 (1:2), 45 °C, 5 h (**29**, 81%; **3**, 99%); (d) (1) Zn powder (3.0 equiv), HCO_2NH_4 (6.0 equiv), THF-MeOH (1:1), rt, 4 h, (2) Amberlite IRC-50 (Na^+ form), MeOH, (3) Sephadex LH-20, MeOH- CH_2Cl_2 (1:1) (85%); (e) (1) pyridine- SO_3 , DMF-pyridine (4:1), 65 °C, 2 h, (2) Amberlite IRC-50 (Na^+ form), MeOH, (3) Sephadex LH-20, MeOH- CH_2Cl_2 (1:1) (69%).

hydrochloric acid in methanol produced lamellarin α (**3**) in 99% yield. Treatment of **3** with pyridine-SO₃ complex in DMF-pyridine followed by ion exchange over Amberlite IRC-50 (Na⁺ form) and Sephadex purification afforded lamellarin α 13,20-disulfate (**4**)¹⁴ in 69% yield. The spectroscopic data of **1** and **4** are identical with those previously reported.^{3,4}

In conclusion, we have succeeded in a divergent synthesis of lamellarin α 20-sulfate (**1**), 13-sulfate (**2**), and 13,20-disulfate (**4**) using **6** as a common intermediate. The synthesis of the other lamellarin sulfate derivatives and their structure-activity relationship studies are in progress.

ACKNOWLEDGEMENTS

The authors wish to thank the president's discretionary fund of Nagasaki University and the Naito Foundation for financial support.

REFERENCES AND NOTES

1. For recent reviews, see: (a) P. Cironi, F. Albericio, and M. Álvarez, *Progress in Heterocyclic Chemistry*, 2004, **16**, 1; (b) C. Bailly, *Curr. Med. Chem. - Anti-Cancer Agents*, 2004, **4**, 363; (c) S. T. Handy and Y. Zhang, *Org. Prep. Proc. Int.*, 2005, **8**, 411; (d) H. Fan, J. Peng, M. T. Hamann, and J.-F. Hu, *Chem. Rev.*, 2008, **108**, 264; (e) D. Pla, F. Albrecio, and M. Álvarez, *Anti-Cancer Agents in Med. Chem.*, 2008, **8**, 746; (f) J. Kluza, P. Marchetti, and C. Bailly, 'Modern Alkaloids: Structure, Isolation, Synthesis and Biology,' ed. by E. Fattorusso and O. Taglialatela-Scafati, Wiley-VCH, Weinheim, 2008, pp. 171-187.
2. M. V. R. Reddy, M. R. Rao, D. Rhodes, M. S. T. Hansen, K. Rubins, F. D. Bushman, Y. Venkateswarlu, and D. J. Faulkner, *J. Med. Chem.*, 1999, **42**, 1901.
3. C. P. Ridley, M. V. R. Reddy, G. Rocha, F. D. Bushman, and D. J. Faulkner, *Bioorg. Med. Chem.*, 2002, **10**, 3285.
4. T. Yamaguchi, T. Fukuda, F. Ishibashi, and M. Iwao, *Tetrahedron Lett.*, 2006, **47**, 3755.
5. (a) M. Iwao, T. Takeuchi, N. Fujikawa, T. Fukuda, and F. Ishibashi, *Tetrahedron Lett.*, 2003, **44**, 4443; (b) N. Fujikawa, T. Ohta, T. Yamaguchi, T. Fukuda, F. Ishibashi, and M. Iwao, *Tetrahedron*, 2006, **62**, 594.
6. Y. Liu, I. F. Lien, S. Ruttgaizer, P. Dove, and S. D. Taylor, *Org. Lett.*, 2004, **6**, 209.
7. G. S. Annapurna and V. H. Deshpande, *Synth. Commun.*, 1983, **13**, 1075.
8. A. I. Meyers and L. Snyder, *J. Org. Chem.*, 1993, **58**, 36.
9. T. Oh-e, N. Miyaara, and A. Suzuki, *J. Org. Chem.*, 1993, **58**, 2201.
10. D. L. Boger, D. R. Soenen, C. W. Boyce, M. P. Hedrick, and Q. Jin, *J. Org. Chem.*, 2000, **65**, 2479.
11. (a) T. Takada, M. Arisawa, M. Gyoten, R. Hamada, H. Tohma, and Y. Kita, *J. Org. Chem.*, 1998, **63**,

- [7698](#); (b) H. Tohma, H. Morioka, S. Takizawa, M. Arisawa, and Y. Kita, [Tetrahedron](#), 2001, **57**, [345](#); (c) H. Hamamoto, G. Anilkumar, H. Tohma, and Y. Kita, [Chem. Eur. J.](#), 2002, **8**, [5377](#).
12. Lamellarin α 13-sulfate (**2**). Mp 265-280 °C (dec.) (sealed capillary); IR (KBr): 3422, 1684, 1432, 1267, 1049 cm^{-1} ; ^1H NMR (400 MHz, 8 mg of **2** in 0.7 mL of $\text{DMSO-}d_6$): δ 3.31 (s, 3H), 3.37 (s, 3H), 3.85 (s, 3H), 3.87 (s, 3H), 6.39 (s, 1H), 6.46 (s, 1H), 7.07 (s, 1H), 7.16 (dd, J = 2.0 and 8.3 Hz, 1H), 7.19 (d, J = 7.3 Hz, 1H), 7.26 (d, J = 8.3 Hz, 1H), 7.36 (s, 1H), 7.71 (d, J = 2.0 Hz, 1H), 9.03 (d, J = 7.3 Hz, 1H); ^{13}C NMR (100 MHz, 8 mg of **2** in 0.7 mL of $\text{DMSO-}d_6$): δ 54.4, 54.5, 55.5, 56.2, 103.2, 103.8, 104.9, 105.5, 107.9, 109.3, 111.4, 113.9, 118.2, 122.2, 123.3, 124.2, 126.0, 127.2, 130.9, 133.5, 143.8, 147.2, 148.4, 148.8, 149.7, 150.3, 154.9. HRFABMS m/z . Calcd for $\text{C}_{29}\text{H}_{22}\text{NNa}_2\text{O}_{11}\text{S}$ [(M+Na) $^+$]: 638.0709. Found: 638.0662.
13. Lamellarin α 20-sulfate (**1**). Mp 258-268 °C (dec.) (sealed capillary) [lit.⁴, mp 263-269 °C (dec.) (sealed capillary)]; IR (KBr): 3422, 1698, 1485, 1418, 1273, 1047 cm^{-1} ; ^1H NMR (400 MHz, 17 mg of **1** in 0.7 mL of $\text{DMSO-}d_6$): δ 3.34 (s, 3H), 3.37 (s, 3H), 3.84 (s, 3H), 3.87 (s, 3H), 6.82 (s, 1H), 6.86 (dd, J = 1.9 and 8.2 Hz, 1H), 7.02 (d, J = 1.9 Hz, 1H), 7.16 (d, J = 8.2 Hz, 1H), 7.18 (s, 1H), 7.26 (d, J = 7.4 Hz, 1H), 7.34 (s, 1H), 7.57 (s, 1H), 9.02 (d, J = 7.4 Hz, 1H); ^{13}C NMR (100 MHz, 17 mg of **1** in 0.7 mL of $\text{DMSO-}d_6$): δ 54.4, 55.0, 55.5, 55.9, 104.7, 105.8, 106.9, 108.0, 108.7, 111.4, 111.5, 112.8, 113.4, 118.2 (118.16), 118.2 (118.24), 120.7, 122.0, 124.2, 127.0, 127.9, 133.4, 143.2, 145.1, 146.6, 148.3, 148.8, 149.0, 149.8, 154.1. HRFABMS m/z . Calcd for $\text{C}_{29}\text{H}_{22}\text{NNa}_2\text{O}_{11}\text{S}$ [(M+Na) $^+$]: 638.0709. Found: 638.0750.
14. Lamellarin α 13,20-disulfate (**4**). Mp 205-210 °C (dec.) (sealed capillary) [lit.³, mp > 260 °C (chars)]; IR (KBr): 1699, 1486, 1419, 1272, 1050 cm^{-1} ; ^1H NMR (400 MHz, $\text{DMSO-}d_6$): δ 3.37 (s, 3H), 3.39 (s, 3H), 3.86 (s, 3H), 3.88 (s, 3H), 6.73 (s, 1H), 7.12 (s, 1H), 7.21 (dd, J = 2.1 and 8.3 Hz, 1H), 7.29 (d, J = 8.3 Hz, 1H), 7.34 (d, J = 7.4 Hz, 1H), 7.42 (s, 1H), 7.58 (s, 1H), 7.75 (d, J = 2.1 Hz, 1H), 9.08 (d, J = 7.4 Hz, 1H); ^{13}C NMR (100 MHz, $\text{DMSO-}d_6$): δ 54.5, 55.0, 55.6, 56.2, 104.8, 105.6, 107.0, 108.1, 108.6, 111.0, 111.5, 112.9, 114.0, 118.3, 122.0, 123.1, 124.2, 125.9, 126.3, 128.2, 133.6, 143.1, 143.9, 145.0, 146.7, 149.1, 150.0, 150.6, 154.2. HRFABMS m/z . Calcd for $\text{C}_{29}\text{H}_{21}\text{NNa}_3\text{O}_{14}\text{S}_2$ [(M+Na) $^+$]: 740.0097. Found: 740.0145.